Wednesday, 22 Jan 2020

You are here

Bisphosphonates and the Risk of Osteonecrosis of the Jaw

Even though oral bisphosphonates are widely used, there is an inordinate concern over the risk of osteonecrosis of the jaw (ONJ).  A new UK study suggests that the risk of ONJ is elevated six fold by the use of biphosphonates.

This UK study examined ONJ amongst those hospital admission with osteonecrosis of the jaw from 521,695 Million Women Study participants.

After a mean follow-up of 8.2 years, 100 women were hospitalized with their first ONJ. One-third (29/100) of the cases had used bisphosphonates.  The absolute risk ONJ hospitalizations for those at age 70 years was 0.09 per 1000 in non-bisphosphonate exposed and 0.69 per 1000 among those who use bisphosphonates (adjusted RR = 6.09, 95% CI 3.83–9.66; p < 0.0001). Bisphosphonates had an excess ONJ risk of 0.6/1000 users over a 5 year period. 

The risk for ONJ was also increased in women with a prior cancer (RR = 3.40, 2.22–5.22, p < 0.0001). 

In this UK population of postmenopausal women, use of oral bisphosphonates was associated with a 6-fold increased risk of hospital admission with osteonecrosis of the jaw.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Should We Screen Younger Postmenopausal Women for Osteoporosis?

Do postmenopausal women, under age 65 years, need a baseline BMD testing? A JAMA Insights review suggests that the absolute risk of fracture is low in this group and that USPSTF guidelines should be considered - that we should be screening women younger than 65 years who are at increased risk of osteoporosis and we should be using a formal risk assessment tool to identify candidates for bone density testing.

Genicular Artery Embolization to Treat Osteoarthritis Knee Pain

A study from the Journal of Vascular and Interventional Radiology has shown that  knee pain secondary to osteoarthritis (OA) may be effectively treated by selective vascular interruption (embolization) showing efficacy and safety in a small pilot trial. 

ACR-Arthritis Foundation Treatment Guidelines for Osteoarthritis

Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released the 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee. The ACR periodically updates guidelines to reflect any advances in management added to the literature since the last publication, which in this case was 2012.

Short-term Benefit with Prednisolone in Hand Osteoarthritis

Lancet reports that prednisolone 10 mg daily for 6 weeks can effectively control the pain of hand osteoarthritis (OA), according to results from the Hand Osteoarthritis Prednisolone Efficacy (HOPE) study. This was a double-blind, randomized, placebo-controlled trial aimed to assess the short-term effects of prednisolone in painful hand OA and synovial inflammation. Patients were required to have hand OA and signs of inflammation in their distal and proximal interphalangeal (DIP/PIP) joints and > 4 DIP/PIP osteoarthritic nodes and at least one DIP/PIP joint with soft swelling/erythema or evidence of synovitis on power Doppler ultrasound. The primary endpoint was finger pain.

Physical Activity Lowers Fracture Risk in Post-Menopausal Women

An analysis from the Women’s Health Initiative study shows that postmenopausal women who participate in vigorous physical activity have a statistically lower risk of total and site-specific fractures